For example, Gil-Raga et al (34) used BRAFV600E and RAS status and the expression of MLH1 (mutL homolog 1)1and MSH2(mutS homolog 2) to divide 105 patients with stage I-III CRC into five molecular subtypes, and to evaluate clinicopathological features and median survival. This evidence concerns the gene MLH1 and colorectal carcinoma.